The goal for the Expanded Access Program is to address an unmet medical need by providing early access to melflufen treatment for RRMM patients who meet all eligibility criteria.
The sites listed below are not the only locations where patients may be able to participate. If you are interested and deemed eligible for the study, Oncopeptides may work with a local oncologist to bring this program to a center near you. Please contact SparkCures at (888) 828-2206 for additional assistance.
SparkCures ID | 1083 |
---|---|
Trial Phase | Expanded Access |
Enrollment | 200 Patients |
Treatments |
|
Tags |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Patients with primary refractory MM are eligible if they meet the criteria for TCR MM. They may meet these criteria for TCR MM if they have received at least one PI, at least one IMiD, and at least one Anti-CD38 mAb in their first line treatment or have had at least 2 prior lines of therapy.
Exclusion Criteria:
Key eligibility criteria listed and is not all inclusive
Please visit the ClinicalTrials.gov page for historical site information.
View CentersApril 19, 2024
Patients may be eligible to receive financial assistance for travel and lodging purposes through Oncopeptides’ partner, Lazarex Cancer Foundation.
SparkCures is working closely with Oncopeptides AB to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors